BR112019008156A2 - methods, compositions and dosage regimens in the treatment or prevention of interferon-gamma related indications - Google Patents

methods, compositions and dosage regimens in the treatment or prevention of interferon-gamma related indications

Info

Publication number
BR112019008156A2
BR112019008156A2 BR112019008156A BR112019008156A BR112019008156A2 BR 112019008156 A2 BR112019008156 A2 BR 112019008156A2 BR 112019008156 A BR112019008156 A BR 112019008156A BR 112019008156 A BR112019008156 A BR 112019008156A BR 112019008156 A2 BR112019008156 A2 BR 112019008156A2
Authority
BR
Brazil
Prior art keywords
methods
compositions
interferon
prevention
treatment
Prior art date
Application number
BR112019008156A
Other languages
Portuguese (pt)
Inventor
De Min Cristina
De Benedetti Fabrizio
Ferlin Walter
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of BR112019008156A2 publication Critical patent/BR112019008156A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se geralmente a composições e métodos de regimes de dosagem para tratar, prevenir e / ou retardar o aparecimento ou progressão de, ou aliviar um sintoma associado com níveis elevados de ifn-gama.The present invention generally relates to dosage regimen compositions and methods for treating, preventing and / or delaying the onset or progression of, or alleviating a symptom associated with high ifn-gamma levels.

BR112019008156A 2016-10-24 2017-10-24 methods, compositions and dosage regimens in the treatment or prevention of interferon-gamma related indications BR112019008156A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662411783P 2016-10-24 2016-10-24
PCT/IB2017/001427 WO2018078442A2 (en) 2016-10-24 2017-10-24 Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications

Publications (1)

Publication Number Publication Date
BR112019008156A2 true BR112019008156A2 (en) 2019-07-02

Family

ID=60957345

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019008156A BR112019008156A2 (en) 2016-10-24 2017-10-24 methods, compositions and dosage regimens in the treatment or prevention of interferon-gamma related indications

Country Status (12)

Country Link
EP (1) EP3528845A2 (en)
JP (2) JP2019532970A (en)
KR (1) KR20190071785A (en)
CN (1) CN110167593A (en)
AU (1) AU2017352033A1 (en)
BR (1) BR112019008156A2 (en)
CA (1) CA3041434A1 (en)
EA (1) EA201990930A1 (en)
IL (1) IL266174B1 (en)
MX (1) MX2019004766A (en)
SG (1) SG11201903659WA (en)
WO (1) WO2018078442A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118165113A (en) * 2016-04-26 2024-06-11 科济生物医药（上海）有限公司 Method for improving immune response cell function
WO2021185832A1 (en) 2020-03-16 2021-09-23 Swedish Orphan Biovitrum Ag New therapeutic treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2000032634A1 (en) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
KR101380570B1 (en) * 2005-01-27 2014-04-01 노비뮨 에스 에이 Human anti-interferon gamma antibodies and methods of use thereof
JP2015505300A (en) * 2011-11-23 2015-02-19 アムジエン・インコーポレーテツド Treatment method using antibody against interferon gamma
CA2985001A1 (en) * 2015-05-07 2016-11-10 Novimmune Sa Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of cxcl9 and other biomarkers

Also Published As

Publication number Publication date
WO2018078442A2 (en) 2018-05-03
CA3041434A1 (en) 2018-05-03
IL266174A (en) 2019-06-30
CN110167593A (en) 2019-08-23
EA201990930A1 (en) 2019-11-29
MX2019004766A (en) 2019-09-27
WO2018078442A3 (en) 2018-08-23
KR20190071785A (en) 2019-06-24
EP3528845A2 (en) 2019-08-28
JP2019532970A (en) 2019-11-14
AU2017352033A1 (en) 2019-06-06
IL266174B1 (en) 2024-06-01
JP2022187025A (en) 2022-12-15
SG11201903659WA (en) 2019-05-30

Similar Documents

Publication Publication Date Title
ECSP20058592A (en) COMPOSITIONS AND METHODS TO TREAT ANEMIA
EA201792545A1 (en) METHODS AND KITS FOR THE TREATMENT OF DEPRESSION
MA39906A (en) Combination therapies for the treatment of cancer
BR112019001615A2 (en) methods and compositions for treating myelofibrosis
BR112017008284A8 (en) ACTIVATED BIFIDOBACTERIA AND METHODS FOR THE USE OF THEM
BR112019005305A2 (en) spirocyclic compounds
BR112016029226A2 (en) methods and compositions for treating ulcers
MX2021009899A (en) Administration and dosage of diaminophenothiazines.
BR112018002550A2 (en) inhibitor resistance mechanism
MY192705A (en) Compositions and methods for treating anemia
PH12019501010A1 (en) Arginase inhibitor combination therapies
BR112018008103A2 (en) celastrol analogs
BR112019001039A2 (en) composition for use in the treatment of major depressive disorder
BR112017007817A2 (en) cancer treatment with immune boosters
BR112017021194A2 (en) spirocyclic compounds
MX2020010269A (en) Methods of treating ulcerative colitis.
BR112018003836A2 (en) btk inhibitor combinations to treat multiple myeloma
BR112017024163A2 (en) bicyclic compounds
BR112017002061A2 (en) oral treatment compositions and regimens
BR112019008156A2 (en) methods, compositions and dosage regimens in the treatment or prevention of interferon-gamma related indications
BR112019008241A2 (en) treatment of nodular prurigo
PH12017501120A1 (en) Crosslinked polydiallymine copolymers for the treatment of type 2 diabetes
BR112015016992A2 (en) use of nicotinic acetylcholine alpha 7 receptor agonists for the treatment, improvement, prevention or delayed progression of fatigue
BR112017004552A2 (en) pharmaceutical compositions
BR112017027692A2 (en) immunotherapeutic dosage regimens comprising pomalidomide and an anti-cs1 antibody for cancer treatment

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]